Investigation of radical treatment method for psoriasis using adipose-derived stem cells

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K17318
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: Hiroshima University (2021); Shimane University (2020)
• Principal Investigator: Ogino Ryohei 広島大学, 医系科学研究科(薬), 助教 (00816035)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: イミキモド誘発乾癬様皮膚炎 / 乾癬モデル / 抗IL-23p19抗体 / 脂肪由来幹細胞 / 炎症性サイトカイン

Outline of Final Research Achievements

The effectiveness of adipose-derived stem cells (ASC) in psoriasis have been reported in several papers, but mechanisms of ASC therapy are unclear. In this study, to reveal the mechanisms underlying the therapeutic effects of ASC transplantation for psoriasis, we tried to culture and transplantation of ASCs derived from lean or diet-induced obesity mouse. However, because large amount of adipocyte-like cells were included in stromal vascular fraction from diet-induced obesity mouse, we could not obtain ASCs from obese mouse. We also planned to use anti-IL-23p19 antibody as a therapeutic control in imiquimod-induced psoriasiform dermatitis in mice, and confirmed anti-IL-23p19 antibody could suppress gene expression of cytokines in IL-23/Th17 axis, but not IL-36. Although our experiments are still preliminary, we established a system to start the desired experiment as soon as the ASC culture method is improved.

Free Research Field

医療薬学

Academic Significance and Societal Importance of the Research Achievements

乾癬には根治的治療法がなく、対症療法となることから、患者は長期間にわたり治療を続ける必要がある。近年登場した抗IL-23p19抗体などの生物学的製剤は高い治療効果を示しているが、それでも効果は完全ではない。本研究においても、抗IL-23p19抗体はIL-23により活性化されるTh17細胞に関連するサイトカインを効果的に抑制したが、IL-36や脾臓の肥大など、抑制できていない炎症反応が存在した。これまでの報告から脂肪由来幹細胞が慢性炎症性疾患に示す治療効果は多面的であるため、Th17細胞の活性化抑制にとどまらず、生物学的製剤では抑制できない炎症反応に効果を示すことが期待される。